Satavaptan - Misplaced Pages

Chemical compound Pharmaceutical compound

Satavaptan
Clinical data

ATC code	none
Identifiers
IUPAC name N-(tert-butyl)-4-{-1'(2'H)-yl]sulfonyl}-3-methoxybenzamide
CAS Number	185913-78-4
PubChem CID	9810773
ChemSpider	32699105
UNII	AJS8S3P31H
ECHA InfoCard	100.211.853
Chemical and physical data
Formula	C₃₃H₄₅N₃O₈S
Molar mass	643.80 g·mol
3D model (JSmol)	Interactive image
SMILES C1COCCN1CCO2CC(CC2)3c4cc(OCC)ccc4N(C3=O)S(=O)(=O)c5ccc(cc5OC)C(=O)NC(C)(C)C
InChI InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)/t24-,33+ Key:QKXJWFOKVQWEDZ-VCCCEUOBSA-N
(what is this?) (verify)

Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009.

References

Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G (November 2006). "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist". Clinical Journal of the American Society of Nephrology. 1 (6): 1154–60. doi:10.2215/CJN.00160106. PMID 17699341.
Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D (July 2008). "Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial". Hepatology. 48 (1): 204–13. doi:10.1002/hep.22293. PMID 18508290.
"Satavaptan". Adis Insight. Springer Nature Switzerland AG.

Oxytocin and vasopressin receptor modulators

Oxytocin

Agonists: Peptide: Aspartocin
Carbetocin
Cargutocin
Demoxytocin
Lipo-oxytocin-1
Merotocin
Nacartocin
Oxytocin
PF-06478939
PF-06655075 (PF1)
TGOT
Vasotocin (argiprestocin); Non-peptide: CA7
LIT-001
TC OT 39
WAY-267464
WJ0679

Vasopressin

V_1A	Agonists: Felypressin Lypressin Ornipressin Selepressin Terlipressin Vasopressin (argipressin) Vasotocin (argiprestocin) Antagonists: Atosiban Balovaptan Conivaptan FR-218944 JNJ-17079166 JNJ-17308616 LIT-001 LY-307174 PF-184563 Relcovaptan RG7713 SRX246 SRX251 TC OT 39 WAY-267464 YM-218 YM-471 YM-35471
V_1B	Agonists: Desmopressin Felypressin Lypressin Ornipressin Terlipressin Vasopressin (argipressin) Vasotocin (argiprestocin) Antagonists: ABT-436 ABT-558 Brezivaptan Nelivaptan ORG-52186 (SCH-740935) TASP-0233278 TASP-0390325 Ligands: TASP-699
V₂	Agonists: Desmopressin Felypressin LIT-001 Lypressin Ornipressin TC OT 39 Terlipressin Vasopressin (argipressin) Vasotocin (argiprestocin) Antagonists: Conivaptan JNJ-17079166 Lixivaptan Mozavaptan RWJ-351647 Satavaptan Tolvaptan YM-471 YM-35471
Unsorted	Antagonists: Balovaptan Ribuvaptan RWJ-339489 VMAX-367 VMAX-372 VMAX-382 YM-222546 Other inhibitors: Demeclocycline Lithium (lithium carbonate)

Others

Carrier proteins: Neurophysin (I, II)

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: